CagriSema vs Cardarine (GW-501516)
A side-by-side research comparison of CagriSema and Cardarine (GW-501516) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Cardarine (GW-501516) |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | GW-501516 (Cardarine, Endurobol) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Discontinued in development (safety concerns; banned in sport) |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Activates the PPAR-delta nuclear receptor, shifting cells toward burning fat for fuel and upregulating genes involved in fatty-acid oxidation and endurance metabolism. |
| Molecular weight | Combination product | 453.50 Da |
| Half-life | 7 days (both components) | ~20-24 hours |
| Bioavailability | High (SubQ) | Oral |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | Commonly cited 10-20 mg/day (research) |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous | Oral |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Cardarine (GW-501516) reported benefits
- Increased endurance (research claims)
- Enhanced fat oxidation
- No hormonal suppression
- Improved lipid profile in some studies
Related comparisons
Research and educational reference only. Not medical advice.